FDA's 1st biosimilar adcomm: a lovefest

From the get-go, the 7 January meeting of the FDA's Oncologic Drugs Advisory Committee (ODAC) was a lovefest between regulators and the filgrastim biosimilar from Novartis and its Sandoz unit, known as Zarxio, which won the panel's unanimous support.